

****Published September 2020****

MarketVIEW: Chikungunya virus vaccines (CAT: VAMV005)

Product Name	:	MarketVIEW: Chikungunya virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>250 slides.pdf) + 1 x MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	Chikungunya virus vaccines
Publication date	:	September 2020
Catalogue No	:	VAMV005

Background

Chikungunya virus (CHIKV) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIKV rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIKV is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection.¹ and during 2018/2019 a further 126 deaths were recorded across the PAHO region.

Although CHIKV is endemic in Africa/Southeast Asia, recently outbreaks have occurred in previously CHIKV free countries, including China, Papua New Guinea, Laos, New Caledonia and Bhutan. In the two years between 2014-2016, a large increase in CHIK transmission occurred in the Americas. The latest CDC appraisal released September 19th, 2019 indicated even more countries (~116) had been affected in Africa, Middle East and Europe.

A number of potential CHIKV vaccine candidates (based on various approaches) are now in various stages of clinical development including those from **Emergent BioSolutions**, **Themis Bio GmbH (Merck & Co)** and **Valneva Austria GmbH**. These candidates have received US and EU fast track regulatory designations underscoring their high medical need, and recently, the **Coalition of Epidemic Preparedness Innovations (CEPI)** has also disbursed funds to ongoing efforts. Regulators have approved new accelerated pathways to licensure based on immunogenicity (ICOP) rather than conducting a Phase III efficacy study. Once proven to be safe, a CHIKV vaccine could be available from 2022/23 onwards and used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent). The **SARS-CoV-2 [COVID-19]** pandemic will force a rethink on the optimum market positioning of a CHIKV vaccine.

¹A Brazil case study is provided in this study

Continued.....

This **MarketVIEW** product is a comprehensive commercial evaluation containing an Executive Presentation (>250 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylactic Chikungunya vaccine to 2035. The prospects of the vaccine in **First time** and **Repeat** Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A newly engineered model for September 2020 now explores a mixed vaccine schedule market, impact of COVID-19 and brand new competitor entrance scenarios. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Chikungunya virus vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference and FDA meeting proceedings etc. Previously published research by **VacZine Analytics** in the field of viral and flavivirus based-pathogens has also been utilised.

PRODUCT CONTENTS:

Published September 2020 (CAT No: VAMV005)

****This product is a [summary presentation \(.pdf\)](#), [1 x forecast models \(.xls\)](#)

Contents – Summary presentation (.pdf)²

Contents
Author's notes
Executive summary
[SECTION 1] Chikungunya virus vaccines: key model outputs
[SECTION 2] Chikungunya virus: disease background
[SECTION 3] Chikungunya virus: disease epidemiology
[SECTION 4] Chikungunya virus: R&D pipeline and competitor activity
[SECTION 5] Chikungunya virus: modelling commercial potential
References/bibliography
About **VacZine Analytics**
Disclaimer

SNAPSHOT

PAGES: ~250 slides fully referenced/sourced. Available in .pdf form

Contents – 1 x vaccine demand models (MS Excel-based)

Worksheets = >100 interconnected

² Full contents i.e. title per slide is available upon request

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$10,995.00**/ GBP **£8,495.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations)

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 927049 / +44 (0) 7952470582

E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and “the spiral logo” are UK Registered Trademarks, 2009

